Log In
BCIQ
Print this Print this
 

BSI-302

  Manage Alerts
Collapse Summary General Information
Company Sanofi
DescriptionAnti-tubulin therapy
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$500.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/27/2009

$500.0M

Undisclosed

Undisclosed

Get a free BioCentury trial today